Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
05:46pm, Monday, 24'th Jul 2023
Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi.
Better Big Biotech Buy: Vertex vs. Biogen
10:09am, Monday, 24'th Jul 2023
Vertex Pharmaceuticals is heading for a big moment -- a regulatory decision on a potential new blockbuster. Biogen recently won regulatory approval for a drug that may become its new growth driver.
4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys
07:54am, Sunday, 23'rd Jul 2023
Barron's Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron
Lilly Joins Biogen as Alzheimer's Drugs Finally Emerge
08:03pm, Friday, 21'st Jul 2023
In trials, Biogen and Eli Lilly have shown that their drugs can slow early-stage decline in the disease. It could be a bonanza for patients—and investors.
Final Trades: Charles Schwab, Biogen & more
05:16pm, Thursday, 20'th Jul 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
12:07pm, Wednesday, 19'th Jul 2023
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Is Biogen Stock a Buy Now?
08:30am, Wednesday, 19'th Jul 2023
Biogen just earned an important approval for an Alzheimer's disease therapy. Even with this milestone, the biotech still faces serious issues worth considering.
At-home Alzheimer's testing is on the horizon, researchers say
08:04am, Wednesday, 19'th Jul 2023
A simple blood test of the type that can be done at home by a patient or family member has shown promise in detecting Alzheimer's, according to research released Wednesday at the Alzheimer's Associati
Biogen, Eli Lilly likely to split the Alzheimer's drug market, analysts say
08:39am, Tuesday, 18'th Jul 2023
Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the Alzheimer's drug market after Lilly on Monday released more details on its late-stage tri
Should You Buy the Dip With Biogen Stock Right Now?
09:45am, Monday, 17'th Jul 2023
Biogen's newest medicine didn't wow the market upon its approval. There are a handful of stumbling blocks that might hamper the drug's potential.
These 2 Numbers Should Scare Every Biogen Shareholder
07:15am, Sunday, 16'th Jul 2023
Biogen's latest drug launch could make it a lot of money through 2028. If it does, it'll reverse a long-running trend of weak growth.
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
08:15am, Thursday, 13'th Jul 2023
The FDA gave full approval for Alzheimer's drug Leqembi in July. Despite the positive news, Biogen's stock didn't take off.
Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug
12:30pm, Monday, 10'th Jul 2023
Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.
Biogen shares ‘an under-owned turnaround story,' Jefferies analysts say
08:58am, Monday, 10'th Jul 2023
Shares of Biogen Inc. BIIB, -3.48%, which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer's treatment Leqembi, “remain an under-owned turnaround story,” and
FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides
08:00am, Monday, 10'th Jul 2023
Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.
